Lung Cancer

Top Story

Researchers develop value-based framework for cancer drug pricing

August 27, 2015

Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.

“Cancer drug prices have been skyrocketing in recent years, and these prices are not linked to the benefit that the drugs provide,” Daniel A. Goldstein, MD, a third-year fellow in the department of hematology and medical oncology at Winship Cancer Institute of Emory University, said in a press release. “Most new cancer drugs cost in excess of $10,000 per month.”

FDA News

FDA grants orphan drug designation to Gilotrif for advanced squamous cell lung carcinoma

August 25, 2015
The FDA granted orphan drug designation to afatinib for the treatment of patients with squamous cell lung carcinoma who experienced disease progression following…
In the Journals

Radial endobronchial ultrasound effectively identifies peripheral lung lesions

August 25, 2015
Radial endobronchial ultrasound-guided bronchoscopy appeared useful for the diagnosis of peripheral lung lesions in a region with high incident tuberculosis, according…
FDA News

FDA grants orphan drug designation to MTG-201 for malignant mesothelioma

August 25, 2015
The FDA granted orphan drug designation to MTG-201 for the treatment of patients with malignant mesothelioma, according to a press release.MTG-201 (MTG Biotherapeutics)…
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: Advancements in immunotherapy drug combinations show promise for multiple cancer types

VIDEO: Advancements in immunotherapy drug combinations show promise for multiple cancer types

June 16, 2015
CHICAGO — Edward S. Kim, MD, chair of solid tumor oncology and investigational therapeutics at the Levine Cancer…
More »
In the Journals

Researchers develop value-based framework for cancer drug pricing

August 27, 2015
Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.“Cancer…
FDA News

FDA grants orphan drug designation to Gilotrif for advanced squamous cell lung carcinoma

August 25, 2015
The FDA granted orphan drug designation to afatinib for the treatment of patients with squamous cell lung carcinoma who experienced disease…
In the Journals

Radial endobronchial ultrasound effectively identifies peripheral lung lesions

August 25, 2015
Radial endobronchial ultrasound-guided bronchoscopy appeared useful for the diagnosis of peripheral lung lesions in a region with high incident…
FDA News

FDA grants orphan drug designation to MTG-201 for malignant mesothelioma

August 25, 2015
The FDA granted orphan drug designation to MTG-201 for the treatment of patients with malignant mesothelioma, according to a press release.MTG-201…
Roy S. Herbst, MD, PhD Cover StoryPublication Exclusive

Immunotherapy ‘revolutionary’ for lung cancer, but questions remain about cost, biomarkers

HemOnc Today, August 25
The potential of immunotherapy to treat several malignancies has generated tremendous excitement in the oncology community, and this optimism has…
Lorenzo Cohen, PhD

Stress and cancer: Mindfulness is pivotal component to improve outcomes

August 24, 2015
Stress hormones are released when the body responds to physical, mental or emotional pressures.These stress hormones — such as epinephrine and…
In the Journals

Vemurafenib shows promise for BRAFV600 -mutated nonmelanoma cancers

August 20, 2015
The BRAF V600 oncogene appeared targetable in certain nonmelanoma cancers, according to the results of a phase 2 study.Further, vemurafenib…
Ella A. Kazerooni, MD, MS FDA News

FDA clears low-dose CT lung cancer screening option

August 17, 2015
GE Healthcare today announced the FDA has issued clearance for the company’s low-dose CT lung cancer screening option for qualified GE…
In the Journals

Treatment delays, missed diagnostic testing common among patients with lung cancer

August 12, 2015
Patients who undergo surgery for lung cancer may experience treatment delays and forgo diagnostic processes that would help determine their optimal…
Sunil Singhal In the Journals

Fluorescent molecular imaging helps identify lung adenocarcinomas

August 11, 2015
Fluorescent molecular imaging helped surgeons visually identify lung adenocarcinomas during pulmonary resection, according to study results.If…
More Headlines »
morganatic-roan
morganatic-roan